Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)

Pierre Fenaux; Aristoteles Giagounidis; Dominik Selleslag; Odile Beyne-Rauzy; Moshe Mittelman; Petra Muus; Stephen D. Nimer; Eva Hellström-Lindberg; Bayard L. Powell; Agnes Guerci-Bresler; Mikkael A. Sekeres; H. Joachim Deeg; Consuelo Del Cañizo; Peter L. Greenberg; Jamile M. Shammo; Barry Skikne; Xujie Yu; Alan F. List

doi:10.1186/s13045-017-0491-2

Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)

Pierre Fenaux^*, Aristoteles Giagounidis, Dominik Selleslag, Odile Beyne-Rauzy, Moshe Mittelman, Petra Muus, Stephen D. Nimer, Eva Hellström-Lindberg, Bayard L. Powell, Agnes Guerci-Bresler, Mikkael A. Sekeres, H. Joachim Deeg, Consuelo Del Cañizo, Peter L. Greenberg, Jamile M. Shammo, Barry Skikne, Xujie Yu, Alan F. List

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Background: Particularly since the advent of lenalidomide, lower-risk myelodysplastic syndromes (MDS) patients with del(5q) have been the focus of many studies; however, the impact of age on disease characteristics and response to lenalidomide has not been analyzed. Methods: We assessed the effect of age on clinical characteristics and outcomes in 286 lenalidomide-treated MDS patients with del(5q) from two multicenter trials. Results: A total of 33.9, 34.3, and 31.8% patients were aged <65 years, ≥65 to <75 years, and ≥75 years, respectively. Age <65 years was associated with less favorable International Prognostic Scoring System (IPSS) risk and additional cytopenias at baseline versus older age groups, significantly lower cytogenetic response rates (p = 0.022 vs. ≥65 to <75 years; p = 0.047 vs. ≥75 years), and higher rates of acute myeloid leukemia (AML) progression (Gray's test, p = 0.013). Lenalidomide was equally well tolerated across age groups, producing consistently high rates of red blood cell transfusion independence ≥26 weeks. Conclusions: Baseline disease characteristics and AML progression appear to be more severe in younger lower-risk MDS patients with del(5q), whereas older age does not seem to compromise the response to lenalidomide. Trial registration: ClinicalTrials.gov

Original language	English (US)
Article number	131
Journal	Journal of Hematology and Oncology
Volume	10
Issue number	1
DOIs	https://doi.org/10.1186/s13045-017-0491-2
State	Published - Jun 26 2017

Funding

Celgene Corporation provided funding for this study. The authors received editorial and writing support provided by Christian Geest, PhD, from Excerpta Medica, supported by Celgene Corporation. The authors had full access to the data and are fully responsible for content and editorial decisions for this manuscript.

Keywords

Acute myeloid leukemia
Age
Lenalidomide
Myelodysplastic syndromes
del(5q)

ASJC Scopus subject areas

Hematology
Molecular Biology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/s13045-017-0491-2

Cite this

Fenaux, P., Giagounidis, A., Selleslag, D., Beyne-Rauzy, O., Mittelman, M., Muus, P., Nimer, S. D., Hellström-Lindberg, E., Powell, B. L., Guerci-Bresler, A., Sekeres, M. A., Deeg, H. J., Del Cañizo, C., Greenberg, P. L., Shammo, J. M., Skikne, B., Yu, X., & List, A. F. (2017). Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q). Journal of Hematology and Oncology, 10(1), Article 131. https://doi.org/10.1186/s13045-017-0491-2

@article{7deb6617c3f848e9bdfb353195b9d136,

title = "Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)",

abstract = "Background: Particularly since the advent of lenalidomide, lower-risk myelodysplastic syndromes (MDS) patients with del(5q) have been the focus of many studies; however, the impact of age on disease characteristics and response to lenalidomide has not been analyzed. Methods: We assessed the effect of age on clinical characteristics and outcomes in 286 lenalidomide-treated MDS patients with del(5q) from two multicenter trials. Results: A total of 33.9, 34.3, and 31.8% patients were aged <65 years, ≥65 to <75 years, and ≥75 years, respectively. Age <65 years was associated with less favorable International Prognostic Scoring System (IPSS) risk and additional cytopenias at baseline versus older age groups, significantly lower cytogenetic response rates (p = 0.022 vs. ≥65 to <75 years; p = 0.047 vs. ≥75 years), and higher rates of acute myeloid leukemia (AML) progression (Gray's test, p = 0.013). Lenalidomide was equally well tolerated across age groups, producing consistently high rates of red blood cell transfusion independence ≥26 weeks. Conclusions: Baseline disease characteristics and AML progression appear to be more severe in younger lower-risk MDS patients with del(5q), whereas older age does not seem to compromise the response to lenalidomide. Trial registration: ClinicalTrials.gov",

keywords = "Acute myeloid leukemia, Age, Lenalidomide, Myelodysplastic syndromes, del(5q)",

author = "Pierre Fenaux and Aristoteles Giagounidis and Dominik Selleslag and Odile Beyne-Rauzy and Moshe Mittelman and Petra Muus and Nimer, {Stephen D.} and Eva Hellstr{\"o}m-Lindberg and Powell, {Bayard L.} and Agnes Guerci-Bresler and Sekeres, {Mikkael A.} and Deeg, {H. Joachim} and {Del Ca{\~n}izo}, Consuelo and Greenberg, {Peter L.} and Shammo, {Jamile M.} and Barry Skikne and Xujie Yu and List, {Alan F.}",

note = "Publisher Copyright: {\textcopyright} 2017 The Author(s).",

year = "2017",

month = jun,

day = "26",

doi = "10.1186/s13045-017-0491-2",

language = "English (US)",

volume = "10",

journal = "Journal of Hematology and Oncology",

issn = "1756-8722",

publisher = "BioMed Central",

number = "1",

}

Fenaux, P, Giagounidis, A, Selleslag, D, Beyne-Rauzy, O, Mittelman, M, Muus, P, Nimer, SD, Hellström-Lindberg, E, Powell, BL, Guerci-Bresler, A, Sekeres, MA, Deeg, HJ, Del Cañizo, C, Greenberg, PL, Shammo, JM, Skikne, B, Yu, X & List, AF 2017, 'Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)', Journal of Hematology and Oncology, vol. 10, no. 1, 131. https://doi.org/10.1186/s13045-017-0491-2

TY - JOUR

T1 - Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)

AU - Fenaux, Pierre

AU - Giagounidis, Aristoteles

AU - Selleslag, Dominik

AU - Beyne-Rauzy, Odile

AU - Mittelman, Moshe

AU - Muus, Petra

AU - Nimer, Stephen D.

AU - Hellström-Lindberg, Eva

AU - Powell, Bayard L.

AU - Guerci-Bresler, Agnes

AU - Sekeres, Mikkael A.

AU - Deeg, H. Joachim

AU - Del Cañizo, Consuelo

AU - Greenberg, Peter L.

AU - Shammo, Jamile M.

AU - Skikne, Barry

AU - Yu, Xujie

AU - List, Alan F.

PY - 2017/6/26

Y1 - 2017/6/26

N2 - Background: Particularly since the advent of lenalidomide, lower-risk myelodysplastic syndromes (MDS) patients with del(5q) have been the focus of many studies; however, the impact of age on disease characteristics and response to lenalidomide has not been analyzed. Methods: We assessed the effect of age on clinical characteristics and outcomes in 286 lenalidomide-treated MDS patients with del(5q) from two multicenter trials. Results: A total of 33.9, 34.3, and 31.8% patients were aged <65 years, ≥65 to <75 years, and ≥75 years, respectively. Age <65 years was associated with less favorable International Prognostic Scoring System (IPSS) risk and additional cytopenias at baseline versus older age groups, significantly lower cytogenetic response rates (p = 0.022 vs. ≥65 to <75 years; p = 0.047 vs. ≥75 years), and higher rates of acute myeloid leukemia (AML) progression (Gray's test, p = 0.013). Lenalidomide was equally well tolerated across age groups, producing consistently high rates of red blood cell transfusion independence ≥26 weeks. Conclusions: Baseline disease characteristics and AML progression appear to be more severe in younger lower-risk MDS patients with del(5q), whereas older age does not seem to compromise the response to lenalidomide. Trial registration: ClinicalTrials.gov

AB - Background: Particularly since the advent of lenalidomide, lower-risk myelodysplastic syndromes (MDS) patients with del(5q) have been the focus of many studies; however, the impact of age on disease characteristics and response to lenalidomide has not been analyzed. Methods: We assessed the effect of age on clinical characteristics and outcomes in 286 lenalidomide-treated MDS patients with del(5q) from two multicenter trials. Results: A total of 33.9, 34.3, and 31.8% patients were aged <65 years, ≥65 to <75 years, and ≥75 years, respectively. Age <65 years was associated with less favorable International Prognostic Scoring System (IPSS) risk and additional cytopenias at baseline versus older age groups, significantly lower cytogenetic response rates (p = 0.022 vs. ≥65 to <75 years; p = 0.047 vs. ≥75 years), and higher rates of acute myeloid leukemia (AML) progression (Gray's test, p = 0.013). Lenalidomide was equally well tolerated across age groups, producing consistently high rates of red blood cell transfusion independence ≥26 weeks. Conclusions: Baseline disease characteristics and AML progression appear to be more severe in younger lower-risk MDS patients with del(5q), whereas older age does not seem to compromise the response to lenalidomide. Trial registration: ClinicalTrials.gov

KW - Acute myeloid leukemia

KW - Age

KW - Lenalidomide

KW - Myelodysplastic syndromes

KW - del(5q)

UR - http://www.scopus.com/inward/record.url?scp=85021334233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021334233&partnerID=8YFLogxK

U2 - 10.1186/s13045-017-0491-2

DO - 10.1186/s13045-017-0491-2

M3 - Article

C2 - 28651604

AN - SCOPUS:85021334233

SN - 1756-8722

VL - 10

JO - Journal of Hematology and Oncology

JF - Journal of Hematology and Oncology

IS - 1

M1 - 131

ER -

Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)

Abstract

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this